Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23178869 | 0.89 | SLC18A3 (0.35) | SLC18A3ALDH1A1KDM4EKMT2AHTT | |
| SCHEMBL10052292 | 0.82 | ARG1 (0.37) | ALDH1A1CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL10092707 | 0.82 | DRD2 (0.42) | GNAI3GNAO1GNAI1 | |
| SCHEMBL12308359 | 0.81 | SLC18A3 (0.39) | SLC18A3ALDH1A1KDM4EKMT2AHTT | |
| SCHEMBL8245487 | 0.80 | NCF1 (0.34) | CARM1PRMT6PRMT1PRMT8GNAI3 | |
| SCHEMBL25075208 | 0.80 | NCF1 (0.39) | ALDH1A1CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL8252286 | 0.80 | CYP1A2 (0.40) | ALDH1A1KMT2ACARM1PRMT6PRMT1 | |
| SCHEMBL19147260 | 0.80 | TP53 (0.37) | ALDH1A1KMT2ALMNACARM1PRMT6 | |
| SCHEMBL27425082 | 0.79 | ACHE (0.34) | CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL25075441 | 0.78 | PRMT6 (0.33) | HTTCARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20220396587-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-15 | — | — | US | disclosed |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | ASCENTAGE PHARMA (SUZHOU) CO., LTD. | 2022-04-26 | — | — | US | disclosed |
| US-11168082-B2 | Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210236474-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| US-20210130401-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | UNIV MICHIGAN REGENTS (US) | 2021-05-06 | — | — | US | disclosed |
| US-20200157091-A1 | PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2020-05-21 | — | — | US | disclosed |
| US-10577363-B2 | Substituted piperidine compounds | Epizyme, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-8791112-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130102586-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8017638-B2 | Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 | SHIONOGI & CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017638-B2 | Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 | SHIONOGI & CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | SMYD3, SMYD2, SNRPD3 | SLC18A3 1755/4885ALDH1A1 1032/4885KDM4E 223/4885 |
| US-20210236474-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS | KDM1A, KDM4A, KDM1B | SLC18A3 2150/4885ALDH1A1 329/4885KDM4E 13/4885 |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | SLC18A3 4783/4885ALDH1A1 1698/4885KDM4E 1257/4885 |
| US-20220396587-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | MCL1, BCL2A1, BCL2L1 | SLC18A3 4846/4885ALDH1A1 369/4885KDM4E 2326/4885 |
| US-20200157091-A1 | PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS | KDM1A, KDM1B, KDM2A | SLC18A3 2700/4885ALDH1A1 1672/4885KDM4E 16/4885 |
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | KRAS, NRAS, HRAS | SLC18A3 4634/4885ALDH1A1 349/4885KDM4E 4054/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | SLC18A3 3239/4885ALDH1A1 1744/4885KDM4E 3345/4885 |
| US-20210130401-A1 | PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION | WDR5, MLLT1, WDR1 | SLC18A3 4743/4885ALDH1A1 3807/4885KDM4E 95/4885 |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | HSD3B1, NR5A1, HSD11B1 | SLC18A3 1973/4885ALDH1A1 203/4885KDM4E 2542/4885 |
| US-11168082-B2 | Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors | KDM1A, KDM1B, KDM2A | SLC18A3 2700/4885ALDH1A1 1672/4885KDM4E 16/4885 |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | KRAS, NRAS, HRAS | SLC18A3 4634/4885ALDH1A1 349/4885KDM4E 4054/4885 |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | SLC18A3 4418/4885ALDH1A1 370/4885KDM4E 1036/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | SLC18A3 4824/4885ALDH1A1 4808/4885KDM4E 288/4885 |
| US-20130102586-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K9, MAP3K19, MAP4K2 | SLC18A3 3795/4885ALDH1A1 4672/4885KDM4E 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.